Cassava Sciences Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Cassava Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares.
View analyst ratings for Cassava Sciences or view top-rated stocks.

5 Wall Street research analysts have issued 1-year target prices for Cassava Sciences' shares. Their SAVA stock forecasts range from $58.00 to $215.00. On average, they predict Cassava Sciences' share price to reach $124.25 in the next twelve months. This suggests a possible upside of 368.7% from the stock's current price.
View analysts' price targets for Cassava Sciences or view top-rated stocks among Wall Street analysts.

Cassava Sciences' stock was trading at $43.70 at the beginning of the year. Since then, SAVA shares have decreased by 39.3% and is now trading at $26.51.
View the best growth stocks for 2022 here.

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Cassava Sciences.

Cassava Sciences, Inc. (NASDAQ:SAVA) released its quarterly earnings data on Thursday, May, 5th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.02.
View Cassava Sciences' earnings history.

Cassava Sciences's stock reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

Some companies that are related to Cassava Sciences include Evotec (EVTCY), Mirati Therapeutics (MRTX), Cerevel Therapeutics (CERE), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Galapagos (GLPG), Cytokinetics (CYTK), Bausch Health Companies (BHC), Harmony Biosciences (HRMY), AbCellera Biologics (ABCL), Amicus Therapeutics (FOLD), Prestige Consumer Healthcare (PBH) and PTC Therapeutics (PTCT).
View all of SAVA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SAVA stock can currently be purchased for approximately $26.51.

Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.06 billion. The company earns $-32.38 million in net income (profit) each year or ($1.16) on an earnings per share basis.

Cassava Sciences employs 24 workers across the globe.

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for Cassava Sciences is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at [email protected], or via fax at 512-501-0414.